Try our Advanced Search for more refined results
Loestrin 24 FE Antitrust Litigation
Case Number:
1:13-md-02472
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Adler Pollock
- Bartlit Beck
- Berger Montague
- Blish & Cavanagh
- Cohen Milstein
- DarrowEverett
- Doyle Lowther
- Duffy & Sweeney
- Dugan Law Firm
- Faruqi & Faruqi
- Foley & Lardner
- FrancoLaw PLLC
- Hach Rose Schirripa
- Hagens Berman
- Hangley Aronchick
- Hilliard & Shadowen
- Kessler Topaz
- Lowenstein Sandler
- Lowey Dannenberg
- Lynch & Pine
- Mancini Carter
- Miller Shah LLP
- Motley Rice
- NastLaw
- Partridge Snow
- Pomerantz LLP
- Radice Law Firm
- Skadden Arps
- Skiermont Derby
- Spector Roseman
- Stranch Jennings
- White & Case
- Wilkinson Stekloff
Companies
- Ahold Delhaize
- Allergan PLC
- CVS Health Corp.
- Fraternal Order of Police
- Health Care Service Corp.
- H‑E‑B LP
- Lupin Ltd.
- Rite Aid Corp.
- Rochester Drug Cooperative Inc.
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- United Food & Commercial Workers International Union
- Warner Chilcott Limited
Sectors & Industries:
-
July 16, 2019
Loestrin Buyers Seek Approval Of $1M Lupin Deal
Loestrin end payors on Monday moved for preliminary approval of their $1 million settlement with Lupin Pharmaceuticals to resolve their portion of litigation accusing the company of working with another pharmaceutical duo to sideline generic alternatives to the widely used birth control drug.
-
July 11, 2019
Loestrin Buyers Fight To Advance Antitrust Case To Trial
Loestrin purchasers accusing Warner Chilcott and Watson Pharmaceuticals of sidelining generic alternatives to the widely used birth control drug have shot back at the drugmakers' efforts to slip their antitrust lawsuit, as the buyers insisted there are still too many questions unanswered to stop the case now.
-
May 20, 2019
Drugmaker, Retailers Strike Deal In Loestrin Antitrust MDL
Lupin Pharmaceuticals cut a deal that will allow it to escape antitrust claims leveled against it by Walgreens, CVS and other retailers that it conspired with two other pharmaceutical companies to keep generic versions of birth control drug Loestrin off the market.
-
October 26, 2018
Only Loestrin Market Matters In Antitrust Row, Retailers Say
Warner Chilcott can't avoid antitrust litigation over sales of its birth control medication Loestrin 24 by claiming it shares the market with all available oral birth control, as the allegations in the suit are much narrower and focus on generic competition, retailers told a Rhode Island federal court in a filing made public Friday.
-
August 21, 2017
Warner Chilcott Must Face Loestrin Pay-For-Delay MDL
Warner Chilcott Co. LLC, Watson Pharmaceuticals Inc. and Lupin Pharmaceuticals Inc. must face multidistrict litigation accusing them of entering into illegal reverse-payment deals to keep a generic of the birth control medication Loestrin off the market, according to an opinion unsealed Monday in Rhode Island federal court.
-
March 16, 2017
Warner Chilcott Wins Discovery In Loestrin Pay-For-Delay MDL
A Rhode Island federal judge on Wednesday granted a discovery bid by Warner Chilcott PLC and others in multidistrict litigation over alleged pay-for-delay settlements for the contraceptive Loestrin, as they look to gather information from a group of pharmacy buyers to determine whether they were able to sell alternatives to Loestrin to patients.
-
January 17, 2017
Drug Cos. Aim To Force Market Discovery In Loestrin MDL
Warner Chilcott PLC and other defendants in multidistrict litigation challenging alleged pay-for-delay settlements over contraceptive Loestrin moved Friday in Rhode Island federal court to force a group of buyers to give up information that may shed light on whether the drug is a market unto itself.
-
August 23, 2016
Warner Says Aggrenox Court Erred In Pay-For-Delay Case
Warner Chilcott PLC told a Rhode Island federal court Monday that a recent ruling in a pay-for-delay suit over blood-clot medication Aggrenox was erroneous and should not be followed in its own multidistrict litigation concerning the contraceptive Loestrin.
-
July 18, 2016
Warner Chilcott Can't Nix Pay-For-Delay Row: Loestrin Buyers
Warner Chilcott PLC should not be allowed to duck pay-for-delay multidistrict litigation concerning the contraceptive pill Loestrin, as amended claims concerning the allegations were properly filed, direct and indirect purchasers told the Rhode Island federal court in separate filings on Friday.
-
July 15, 2016
Retailers Say Birth-Control Drugmaker Stifled Generics
Retailers accusing drugmakers of conspiring to keep generic versions of the birth control pill Loestrin 24 off the market urged the Rhode Island federal judge overseeing the multidistrict litigation to keep their claims alive, saying they consist of specific allegations of anti-competitive behavior that can't be ignored.
- ← Previous
- 1
- 2
- 3
- Next →